Nectin Therapeutics Ltd

About Nectin Therapeutics Ltd

Nectin Therapeutics is focused on developing breakthroughs in immuno-oncology therapies to expand their reach. They aim to address the issue that 80% of cancer patients do not respond to approved immuno-oncology therapies by discovering tumor escape and resistance mechanisms and developing new candidates to overcome resistance to current treatments.

Products & Services

Targeted Immunotherapies:A diverse pipeline of novel immuno-oncology (IO) antibodies and antibody-drug conjugates (ADCs).

Anti-PVR Asset:An asset targeting PVR expression, identified as a rate-limiting factor for approved immune checkpoint inhibitors (ICIs), currently in phase 1 of clinical trials.

Specialties

Immuno-Oncology (IO) Antibodies Antibody-Drug Conjugates (ADCs) Tumor Escape and Resistance Mechanisms

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B - II T: - FT: Series B - II	A: 10000000 MR: - FA: $10 million FAN: 10000000	D: 2024-05-06 FD: 2024-05-06	1 investors

Series B - II Latest

2024-05-06

$10.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

F

Fabian Tenenbaum

Chief Executive Officer

LinkedIn (Pro only)

P

Pini Tsukerman

Chief Scientific Officer

K

Keren Paz

Chief Development Officer

LinkedIn (Pro only)

E

Eric Rowinsky

Acting Chief Medical Officer

G

Guy Cinamon

Vice-President, R&D

L

Lior Buchman

CFO, Integra Holdings Ltd.

View 12 more team members with Pro

Unlock Full Team Directory

Recent News